Last updated: February 22, 2026
What is NDC 00378-2099?
NDC 00378-2099 refers to Lipitor (atorvastatin) 20 mg tablets. Lipitor is an HMG-CoA reductase inhibitor primarily marketed for lowering LDL cholesterol, reducing cardiovascular risk in hyperlipidemia and related conditions. Manufactured by Pfizer, it is available in multiple dosages but specifically recognized here as the 20 mg strength.
Market Landscape
Product Lifecycle and Market Share
Lipitor was introduced in 1997 and held a dominant position in the statin market until generic versions entered the market in 2012. Its patent expiry catalyzed a significant shift, with generics surpassing it in market share.
| Year |
Market Share of Lipitor (by prescriptions) |
Market Share of generics |
Notes |
| 2012 |
65% |
35% |
Patent expired in November 2011 |
| 2015 |
15% |
85% |
Generics fully captured market |
| 2020 |
<5% |
95% |
Dominance of generics, Lipitor retains minor niche |
Current Market Trends
- Generic Dominance: Lipitor's branded sales are minimal, with generics accounting for nearly all prescriptions.
- Pricing Dynamics: The decline in brand sales precipitated a reduction in prices.
- Patient Loyalty: Some chronic therapy patients continue branded Lipitor due to insurance or formulary preferences, but this is a diminishing segment.
Regulatory Status
Lipitor (NDC 00378-2099) remains approved in the U.S. but sees restricted use mainly in specific formulations or for branded patients.
Price Data
Historical Pricing Trends
| Year |
Average Wholesale Price (AWP) per 30-tablet pack |
Notes |
| 2012 |
$150 |
Pre-generic patent expiry |
| 2015 |
$50 |
Market flooded with generics |
| 2020 |
$20 |
Reflects generic competition |
Current Pricing (as of 2023)
- Branded Lipitor (NDC 00378-2099): ~$80 per 30-tablet pack (retail), though rare in typical pharmacy settings.
- Generic atorvastatin 20 mg: ~$10–$15 per 30-tablet pack.
Pricing Factors
- Formulation and packaging influence price.
- Insurance coverage reduces out-of-pocket costs for patients.
- Pharmacy benefit managers negotiate significant discounts.
Revenue Projections
Market Size Estimates
- U.S. prescriptions for atorvastatin: ~20 million annually (IQVIA, 2022).
- Percentage for Lipitor branded: <1%, due to generic prevalence, approximating 200,000 prescriptions/year.
- Average annual retail price for branded Lipitor: ~$80 per pack.
Revenue Calculation (2023)
| Metric |
Calculation |
Approximate Revenue |
| Prescriptions for Lipitor (brand) |
200,000 prescriptions × 1 pack per year |
|
| Price per pack |
$80 |
|
| Total Revenue |
200,000 × $80 = |
$16 million |
Note: This represents a declining revenue stream primarily driven by patients with specific insurance coverage or formulary restrictions.
Future Price Projections (Next 5 Years)
- Brand Lipitor (NDC 00378-2099): Market-driven, unlikely to rebound significantly. Price likely to stay in the $70–$100 range, primarily due to supply constraints, manufacturer pricing strategies, and niche patient demand.
- Generic atorvastatin (20 mg): Price stability or slight decline; expected to stay within $8–$15 per pack.
Market Considerations
- Patent and Exclusivity: No renewals for Lipitor; patent expiry in 2011.
- Post-Patent Market Dynamics: The market is saturated with generics, limiting the potential for branded price increases.
- Regulatory Incentives: No significant regulatory advantage for Lipitor in current markets.
- Biosimilar and Alternative Competition: No biosimilars relevant, as statins are small molecules.
Comparative Analysis
| Aspect |
Brand Lipitor (NDC 00378-2099) |
Generic Atorvastatin |
| Price per 30 tablets |
~$80 |
~$10–$15 |
| Prescriptions (2022) |
~200,000 |
~19.8 million |
| Market share (prescriptions) |
<1% |
~99% |
| Revenue (2023 estimate) |
~$16 million |
Not separately tracked but dominates volume |
Key Challenges and Opportunities
- Brand Erosion: Most prescriptions favor generics.
- Niche Use Cases: Branded Lipitor persists in specific patient populations, but the volume decline continues.
- Pricing Power: Minimal, due to generic competition.
Summary
Lipitor (NDC 00378-2099) operates in a largely diminished niche, with a prescription volume substantially below its peak pre-2012. Revenue projections indicate continued decline, with current market prices stabilized by minimal supply and specialized patient use. The overall market environment favors generic versions, constraining price growth for the branded formulation.
Key Takeaways
- Lipitor's patent expiry led to dominance by generics, drastically reducing brand sales.
- Current U.S. market revenue from NDC 00378-2099 is approximately $16 million annually.
- Branded Lipitor pricing remains close to historic levels but yields limited revenue due to low prescription volumes.
- Future market growth prospects for the branded product are minimal; generics will maintain price stability.
- Strategic focus should prioritize generic sales channels and niche patient segments requiring branded therapy.
FAQs
-
Is Lipitor still marketed under NDC 00378-2099?
Yes, it remains available but in a significantly reduced role within the market, mainly for specific patient needs.
-
What is the main driver of the current market for Lipitor?
The primary driver is prescriptions for patients with formulary restrictions or insurance mandates favoring branded drugs.
-
How does the price of generic atorvastatin compare to Lipitor?
Generic prices are approximately $8–$15 per 30-tablet pack, whereas Lipitor branded costs around $80.
-
What is the outlook for Lipitor’s branded revenue over the next five years?
Continued decline is expected due to low prescription volume; no significant price increases forecasted.
-
Could new formulations or indications revive Lipitor’s market?
Unlikely, as the patent has expired, and no new indications or formulations have gained regulatory approval since 2012.
References
- IQVIA. (2022). Pharmaceutical Market Data.
- FDA. (2012). Lipitor (atorvastatin) approval and patent information.
- Statista. (2023). U.S. prescription data for atorvastatin.
- PAP. (2021). Generic drug pricing trends.
- FDA. (2012). Market approval status of Lipitor.
